The Five Economic Risks Pharma Can't Treat As Background Noise

Over the next one to two years, drugmakers face five overlapping economic pressures, including price cuts, revenue compression, and supply chain fragmentation. Together, these forces are changing which medicines get developed, where they are made, and which countries see them first. The effects are already visible. Most-favored-nation pricing, which ties U.S. prices to lower prices overseas, is leading companies to delay or drop launches in lower-priced markets, and at least one cholesterol drug has already been withdrawn from a European country.

For development teams, these pressures reach back to the earliest decisions: which programs move forward, where products are made and launched, and how quickly therapies reach patients. This article explains each risk, why it matters, and which internal functions need to respond together. It also offers guidance for smaller biotechs with limited in-house expertise. Read on to learn how to build pricing, reimbursement, and policy risk into your portfolio and development decisions now, before they stall a promising program later.